These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33404141)

  • 1. Effectiveness of incentivised adherence and abstinence monitoring in buprenorphine maintenance: a pragmatic, randomised controlled trial.
    Elarabi HF; Shawky M; Mustafa N; Radwan D; Elarasheed A; Yousif Ali A; Osman M; Kashmar A; Al Kathiri H; Gawad T; Kodera A; Al Jneibi M; Adem A; Lee AJ; Marsden J
    Addiction; 2021 Sep; 116(9):2398-2408. PubMed ID: 33404141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower buprenorphine elimination rate constant is associated with lower opioid use.
    Elarabi HF; Lee AJ; Adem A; Elrasheed A; Marsden J; Al Ghaferi H
    Psychopharmacology (Berl); 2022 Oct; 239(10):3213-3221. PubMed ID: 35953563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suboxone Treatment and Recovery Trial (STAR-T): Study Protocol for a Randomised Controlled Trial of Opioid Medication Assisted Treatment with Adjunctive Medication Management Using Therapeutic Drug Monitoring and Contingency Management.
    Elarabi H; Elrasheed A; Ali A; Shawky M; Hasan N; Gawad TA; Adem A; Marsden J
    J Addict; 2019; 2019():2491063. PubMed ID: 30956839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder.
    Greenwald MK; Wiest KL; Haight BR; Laffont CM; Zhao Y
    Harm Reduct J; 2023 Dec; 20(1):173. PubMed ID: 38042801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.
    Marsden J; Kelleher M; Hoare Z; Hughes D; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Scott G; Turner S; Vanderwaal R; Wareham A; Gilvarry E; Mitcheson L
    Trials; 2022 Aug; 23(1):697. PubMed ID: 35986418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial.
    Marsden J; Kelleher M; Gilvarry E; Mitcheson L; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hardy W; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Vanderwaal R; Wareham A; Hughes D; Hoare Z
    EClinicalMedicine; 2023 Dec; 66():102311. PubMed ID: 38045803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study.
    Bakouni H; McAnulty C; Tatar O; Socias ME; Le Foll B; Lim R; Ahamad K; Jutras-Aswad D;
    Am J Addict; 2023 Sep; 32(5):469-478. PubMed ID: 37308805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic.
    Heil J; Salzman M; Hunter K; Baston KE; Milburn C; Schmidt R; Haroz R; Ganetsky VS
    J Subst Use Addict Treat; 2024 Jan; 156():209183. PubMed ID: 37879433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of buprenorphine initial outpatient maintenance and dose taper response among non-treatment-seeking heroin dependent volunteers.
    Woodcock EA; Lundahl LH; Greenwald MK
    Drug Alcohol Depend; 2015 Jan; 146():89-96. PubMed ID: 25479914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse.
    Rudolph KE; Shulman M; Fishman M; Díaz I; Rotrosen J; Nunes EV
    Addiction; 2022 Mar; 117(3):637-645. PubMed ID: 34338389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonidine Maintenance Prolongs Opioid Abstinence and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment.
    Kowalczyk WJ; Phillips KA; Jobes ML; Kennedy AP; Ghitza UE; Agage DA; Schmittner JP; Epstein DH; Preston KL
    Am J Psychiatry; 2015 Aug; 172(8):760-7. PubMed ID: 25783757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
    Hser YI; Zhu Y; Fei Z; Mooney LJ; Evans EA; Kelleghan A; Matthews A; Yoo C; Saxon AJ
    Addiction; 2022 Jan; 117(1):151-161. PubMed ID: 34105213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans.
    Petrakis I; Springer SA; Davis C; Ralevski E; Gu L; Lew R; Hermos J; Nuite M; Gordon AJ; Kosten TR; Nunes EV; Rosenheck R; Saxon AJ; Swift R; Goldberg A; Ringer R; Ferguson R
    Addict Sci Clin Pract; 2022 Jan; 17(1):6. PubMed ID: 35101115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults.
    Marsch LA; Moore SK; Borodovsky JT; Solhkhah R; Badger GJ; Semino S; Jarrett K; Condon KD; Rossettie K; Vincent P; Hajizadeh N; Ducat E
    Addiction; 2016 Aug; 111(8):1406-15. PubMed ID: 26918564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations.
    Winhusen T; Lofwall M; Jones HE; Wilder C; Lindblad R; Schiff DM; Wexelblatt S; Merhar S; Murphy SM; Greenfield SF; Terplan M; Wachman EM; Kropp F; Theobald J; Lewis M; Matthews AG; Guille C; Silverstein M; Rosa C
    Contemp Clin Trials; 2020 Jun; 93():106014. PubMed ID: 32353544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polysubstance Use in Adults With Opioid Use Disorder Receiving Buprenorphine Maintenance.
    Elarabi HF; Radwan DN; Adem A; Marsden J; Lee AJ
    J Addict Med; 2023 Jan-Feb 01; 17(1):74-78. PubMed ID: 35793664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy Dose Mediates the Relationship Between Buprenorphine/Naloxone and Opioid Treatment Outcomes in Youth Receiving Medication for Opioid Use Disorder Treatment.
    Hammond CJ; Kady A; Park G; Vidal C; Wenzel K; Fishman M
    J Addict Med; 2022 Mar-Apr 01; 16(2):e97-e104. PubMed ID: 33973923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.